Business Acquisitions Business Acquisitions (Details) (USD $)	3 Months Ended				6 Months Ended				12 Months Ended	3 Months Ended	12 Months Ended		3 Months Ended			0 Months Ended	3 Months Ended	6 Months Ended							12 Months Ended		12 Months Ended			12 Months Ended		3 Months Ended		3 Months Ended		3 Months Ended		3 Months Ended			12 Months Ended	3 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		12 Months Ended		3 Months Ended		3 Months Ended		12 Months Ended			3 Months Ended		3 Months Ended							12 Months Ended			3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended			3 Months Ended		6 Months Ended			12 Months Ended				3 Months Ended
	Dec. 28, 2013		Dec. 29, 2012		Dec. 28, 2013		Dec. 29, 2012		Jun. 29, 2013	Dec. 28, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Rosemont Pharmaceuticals Ltd. [Domain]	Dec. 29, 2012 Cobrek Pharmaceuticals, Inc. [Domain]	Dec. 28, 2012 Cobrek Pharmaceuticals, Inc. [Domain]	May 29, 2008 Cobrek Pharmaceuticals, Inc. [Domain]	Dec. 28, 2013 Elan Corporation [Member]	Dec. 28, 2013 Elan Corporation [Member]	Dec. 28, 2013 Elan Corporation [Member]	Dec. 29, 2012 Elan Corporation [Member]	Dec. 18, 2013 Elan Corporation [Member]	Dec. 18, 2013 Perrigo Company [Member]	Dec. 28, 2013 Vedants Drug and Fine Chemicals Private Ltd [Member]	Jun. 10, 2013 Vedants Drug and Fine Chemicals Private Ltd [Member]	Aug. 06, 2009 Vedants Drug and Fine Chemicals Private Ltd [Member]	Jun. 29, 2013 Fera Pharmaceuticals, LLC [Domain]	Jun. 17, 2013 Fera Pharmaceuticals, LLC [Domain]	Jun. 29, 2013 Velcera, Inc. [Domain]	Apr. 01, 2013 Velcera, Inc. [Domain]	Dec. 28, 2012 Cobrek Pharmaceuticals [Member]	Jun. 29, 2013 Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Sergeant's Pet Care Products, Inc. [Domain]	Mar. 30, 2013 Licensing Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Licensing Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Licensing Agreements [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Licensing Agreements [Member] Velcera, Inc. [Domain]	Mar. 30, 2013 Exclusive technology agreements [Member] Cobrek Pharmaceuticals [Member]	Feb. 11, 2013 Trademarks and Trade Names [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Trademarks and Trade Names [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Trademarks and Trade Names [Member] Velcera, Inc. [Domain]	Oct. 01, 2012 Trademarks and Trade Names [Member] Sergeant's Pet Care Products, Inc. [Domain]	Apr. 30, 2014 Licensing Agreements [Member]	Dec. 28, 2013 Licensing Agreements [Member] Elan Corporation [Member]	Dec. 18, 2013 Licensing Agreements [Member] Elan Corporation [Member]	Dec. 28, 2013 Prialt [Member] Elan Corporation [Member]	Dec. 18, 2013 Prialt [Member] Elan Corporation [Member]	Jun. 29, 2013 favorable supply agreement [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 favorable supply agreement [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Jun. 29, 2013 Customer Relationships [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Customer Relationships [Member] Velcera, Inc. [Domain]	Jun. 29, 2013 Customer Relationships [Member] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Customer Relationships [Member] Sergeant's Pet Care Products, Inc. [Domain]	Mar. 30, 2013 Developed Technology Rights [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Developed Technology Rights [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Developed Technology Rights [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 17, 2013 Developed Technology Rights [Member] Fera Pharmaceuticals, LLC [Domain]	Jun. 29, 2013 Developed Technology Rights [Member] Sergeant's Pet Care Products, Inc. [Domain]	Oct. 01, 2012 Developed Technology Rights [Member] Sergeant's Pet Care Products, Inc. [Domain]	Feb. 11, 2013 In Process Research and Development [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Mar. 30, 2013 Noncompete Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Feb. 11, 2013 Noncompete Agreements [Member] Rosemont Pharmaceuticals Ltd. [Domain]	Jun. 29, 2013 Noncompete Agreements [Member] Velcera, Inc. [Domain]	Apr. 01, 2013 Noncompete Agreements [Member] Velcera, Inc. [Domain]	Oct. 01, 2012 Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Apr. 01, 2013 Purchase Price Allocation Adjustments [Member] Velcera, Inc. [Domain]	Oct. 01, 2012 Purchase Price Allocation Adjustments [Member] Sergeant's Pet Care Products, Inc. [Domain]	Dec. 28, 2012 Final Valuation [Domain] Cobrek Pharmaceuticals [Member]	Oct. 01, 2012 Final Valuation [Domain] Sergeant's Pet Care Products, Inc. [Domain]	Apr. 30, 2015 Minimum [Member] Licensing Agreements [Member]	Jun. 29, 2013 Minimum [Member] Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Jun. 29, 2013 Maximum [Member] Noncompete Agreements [Member] Sergeant's Pet Care Products, Inc. [Domain]	Dec. 28, 2013 Consumer Healthcare [Member]	Dec. 29, 2012 Consumer Healthcare [Member]	Dec. 28, 2013 Consumer Healthcare [Member]	Dec. 29, 2012 Consumer Healthcare [Member]	Jun. 29, 2013 Consumer Healthcare [Member]	Dec. 28, 2013 Rx Pharmaceuticals [Member]	Dec. 29, 2012 Rx Pharmaceuticals [Member]	Dec. 28, 2013 Rx Pharmaceuticals [Member]	Dec. 29, 2012 Rx Pharmaceuticals [Member]	Jun. 29, 2013 Rx Pharmaceuticals [Member]	Dec. 28, 2013 Nutritionals [Member]	Dec. 29, 2012 Nutritionals [Member]	Dec. 28, 2013 Nutritionals [Member]	Dec. 29, 2012 Nutritionals [Member]	Jun. 29, 2013 Nutritionals [Member]	Dec. 28, 2013 Specialty Sciences [Member]	Dec. 29, 2012 Specialty Sciences [Member]	Dec. 28, 2013 Specialty Sciences [Member]	Dec. 29, 2012 Specialty Sciences [Member]	Jun. 29, 2013 Specialty Sciences [Member]	Apr. 30, 2015 Trench 1 - $0 - $2 billion in sales [Member] Licensing Agreements [Member]	Apr. 30, 2015 Trench 1 - $0 - $2 billion in sales [Member] Maximum [Member] Licensing Agreements [Member]	Apr. 30, 2015 Trench 2 - over $2 billion in sales [Member] Licensing Agreements [Member]	Apr. 30, 2015 Trench 2 - over $2 billion in sales [Member] Minimum [Member] Licensing Agreements [Member]	Dec. 28, 2013 Trench 1 - up to $12.5 million in sales [Member] Prialt [Member]	Dec. 28, 2013 Trench 1 - up to $12.5 million in sales [Member] Minimum [Member] Prialt [Member]	Dec. 28, 2013 Trench 1 - up to $12.5 million in sales [Member] Maximum [Member] Prialt [Member]	Dec. 28, 2013 Trench 2 - $12.5 - $20 million in sales [Member] Prialt [Member]	Dec. 28, 2013 Trench 2 - $12.5 - $20 million in sales [Member] Minimum [Member] Prialt [Member]	Dec. 28, 2013 Trench 2 - $12.5 - $20 million in sales [Member] Maximum [Member] Prialt [Member]	Dec. 28, 2013 Trench 3 - $20 - $35 million in sales [Member] Prialt [Member]	Dec. 28, 2013 Trench 3 - $20 - $35 million in sales [Member] Minimum [Member] Prialt [Member]	Dec. 28, 2013 Trench 3 - $20 - $35 million in sales [Member] Maximum [Member] Prialt [Member]	Dec. 28, 2013 Trench 4 - $35 - $50 million in sales [Member] Prialt [Member]	Dec. 28, 2013 Trench 4 - $35 - $50 million in sales [Member] Minimum [Member] Prialt [Member]	Dec. 28, 2013 Trench 4 - $35 - $50 million in sales [Member] Maximum [Member] Prialt [Member]	Dec. 28, 2013 Trench 5 - Over $50 million in sales [Member] Prialt [Member]	Dec. 28, 2013 Trench 5 - Over $50 million in sales [Member] Minimum [Member] Prialt [Member]
Business Acquisition [Line Items]
Total consideration / Net assets acquired												$ 282,900,000								$ 9,452,400,000						$ 110,600,000		$ 175,100,000			$ 285,000,000																																			$ 51,500,000	$ 285,000,000
Business Acquisition, Cash Exchange per share																				$ 6.25
Exchange ratio per share																				0.07636
Business Acquisition, Percentage of Voting Interests Acquired														81.50%						29.00%	71.00%		15.00%
Total acquisition-related costs											2,000,000						269,000,000	283,700,000							100,000		1,100,000			2,000,000
Administration expense	154,400,000		60,200,000		233,200,000		113,300,000										93,700,000	105,700,000
Interest, net	29,700,000		15,300,000		51,100,000		31,200,000										9,000,000	10,000,000
Other expense, net	4,100,000		100,000		5,100,000		0										500,000	2,200,000
Loss on extinguishment of debt	165,800,000		0		165,800,000		0										165,800,000	165,800,000
Total value of Perrigo shares issued to Elan shareholders																				6,117,200,000
Cash consideration paid at $6.25 per Elan share																				3,223,200,000	0.01
Elan shares outstanding as of December 18, 2013																				515,700,000
Total Company shares issued to acquired company shareholders																				39,400,000
Perrigo per share value at transaction close on December 18, 2013																				$ 155.34
Cash consideration paid for vested Elan stock options and share awards																				112,000,000
Cash consideration paid for unvested Elan stock options and awards																				15,600,000
Cash and cash equivalents												2,100,000								1,807,300,000								18,900,000
Investment securities (Current and noncurrent)																				100,000,000
Accounts receivable												10,600,000								44,200,000								6,300,000																																							19,700,000
Prepaids and other current assets																				27,100,000
Property and equipment												13,100,000								9,200,000								600,000																																							25,400,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Noncurrent												200,000																7,900,000																																						3,600,000	1,500,000
Goodwill	3,187,300,000				3,187,300,000				1,089,300,000			147,000,000								2,076,600,000						2,800,000		62,500,000																																					12,000,000	15,300,000	80,200,000				705,800,000		705,800,000		279,900,000	717,200,000		717,200,000		385,500,000	423,200,000		423,200,000		331,700,000	1,245,300,000		1,245,300,000		0
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Equity Method Investments																				66,300,000
Definite-lived intangible assets												148,200,000								6,111,000,000								135,300,000			135,400,000																								107,000,000									3,000,000		51,100,000	135,400,000
Other non-current assets												800,000								27,100,000								400,000																																						300,000	3,000,000
Total assets acquired												331,600,000								10,268,800,000						111,100,000		241,600,000																																						70,300,000	302,900,000
Business Combination, Customer Related Accruals and Allowances																										500,000
Accounts payable												2,600,000								2,000,000								6,500,000																																							13,700,000
Accrued expenses												7,600,000								89,800,000								4,800,000																																							4,200,000
Deferred tax liabilities												36,000,000								702,200,000								48,200,000																																						18,800,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other												2,500,000																7,000,000
Other non-current liabilities																				22,400,000
Total liabilities assumed												48,700,000								816,400,000						500,000		66,500,000																																						18,800,000	17,900,000
Amount of goodwill allocated to other business segments																				831,300,000
Goodwill, Acquired During Period					2,076,600,000																																																																				423,700,000					316,100,000					91,500,000					1,245,300,000
Royalty rate as a percent of net sales																																									12.00%																																																		18.00%		25.00%		7.00%			10.25%			17.50%			13.50%			10.25%
Write-off of in process research and development	6,000,000		0		6,000,000		0			2,000,000
Net sales	979,000,000	[1]	883,000,000	[1]	1,912,400,000	[1]	1,652,700,000	[1]								7,400,000																																																				0			536,300,000	539,300,000	1,074,800,000	989,700,000		246,600,000	162,500,000	450,200,000	325,500,000		139,700,000	121,900,000	268,700,000	225,300,000		7,400,000	0	7,400,000	0			2,000,000,000		2,000,001,000		0	12,500,000		12,500,000	20,000,000		20,000,000	35,000,000		35,000,000	50,000,000		50,000,000
Other intangible assets acquired												148,200,000																135,300,000					3,600,000		116,000,000		17,300,000		7,600,000	33,000,000			6,100,000,000		11,000,000		25,000,000		8,700,000		10,000,000		114,600,000				66,100,000	11,200,000		1,500,000		3,000,000	1,300,000
Acquired intangible assets, average estimated useful lives (in years)																																14 years		10 years		12 years		25 years				20 years		10 years		7 years		20 years		20 years		7 years		15 years		10 years			3 years		3 years								1 year	3 years
Operating Income (Loss)	86,600,000	[1]	163,900,000	[1]	266,200,000	[1]	320,400,000	[1]								(19,000,000)																																																							89,500,000	86,100,000	179,500,000	165,400,000		100,400,000	64,100,000	183,500,000	132,600,000		13,300,000	7,200,000	21,000,000	11,000,000		(19,000,000)	0	(19,000,000)	0
Restructuring Charges	14,900,000		0		17,000,000		0		2,900,000							14,300,000
Net sales																		2,004,600,000	1,653,000,000
Net income (loss)																		24,900,000	(337,100,000)
Payment for Business Combination, Cash Payment														42,000,000								7,200,000				88,400,000		156,200,000
Contingent consideration																										22,200,000
Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage															18.50%									85.00%
Investment Owned, at Cost															12,600,000									11,500,000
Inventory												9,600,000														1,300,000		9,700,000																																							37,700,000
Inventory Fair Value Adjustment											3,200,000																			7,700,000
Fixed Assets Fair Value Adjustment											4,900,000																			6,100,000
Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value																													9,500,000
Loss on sale of investment	0		3,000,000		0		3,000,000						3,000,000
Business Combination, Integration Related Costs													1,500,000														2,700,000
Intangible assets amortization expense	$ 43,800,000	[1]	$ 21,600,000	[1]	$ 73,600,000	[1]	$ 40,300,000	[1]								$ 8,700,000																																																							$ 5,300,000	$ 4,900,000	$ 10,600,000	$ 7,100,000		$ 21,500,000	$ 8,500,000	$ 37,700,000	$ 16,900,000		$ 7,400,000	$ 7,300,000	$ 14,700,000	$ 14,600,000		$ 8,700,000	$ 0	$ 8,700,000	$ 0

[1] {F|ahBzfndlYmZpbGluZ3MtaHJkcmoLEgZYTUxEb2MiXlhCUkxEb2NHZW5JbmZvOjk5YTAwYzNkYmVjMTQxMTc4MWMyY2U1MWJmNmQ2MzI4fFRleHRTZWxlY3Rpb246QUU2MEJEQzJDRTEzRTZDQjE0OTM1N0VGREY4QTAxNTcM}